source
- Biotech firms rush to develop gene-editing cure for rare alpha-1 antitrypsin deficiencyA wave of biotech companies is intensifying efforts to cure alpha-1 antitrypsin deficiency (AATD), a rare liver and lung disorder, using gene-editing approaches. Companies such as Beam, Wave Life…
- Boston Scientific unveils major restructuring, plots job cuts amid savings driveMedical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally.